Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on March 31, 2026. The filing pertains to a commercial update regarding the U.S. launch of LYMPHIR® (denileukin diftitox-cxdl), issued by Citius Oncology, Inc., the registrant's majority-owned subsidiary.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial results.
Material Changes
The material event reported is the issuance of a press release by Citius Oncology, Inc. on March 31, 2026, detailing a commercial update on the U.S. launch of LYMPHIR®. No quantitative financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary regarding the commercial update is contained within the attached press release (Exhibit 99.1), which is incorporated by reference. This Form 8-K does not contain standalone guidance, risk factors, or contingency details beyond the reference to the subsidiary's announcement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 31, 2026) for specific details on the LYMPHIR® commercial launch update.
- Verify the ownership structure and financial impact of Citius Oncology, Inc. as a majority-owned subsidiary.
- Check subsequent filings for any financial data related to the commercial launch mentioned in this report.